ストックスクリーナーアプリを入手
123.32
1.71%
1.9812
前日終値:
$121.34
開ける：
$122.25
24時間の取引高:
2.94M
Relative Volume:
0.41
時価総額：
$153.05B
収益：
$29.05B
当期純損益:
$8.11B
株価収益率:
19.10
EPS:
6.4563
ネットキャッシュフロー:
$9.16B
1週間 パフォーマンス:
+0.81%
1か月 パフォーマンス:
+0.70%
6か月 パフォーマンス:
+12.91%
1年 パフォーマンス:
+33.59%
1日の値動き範囲:
$121.00
$123.74
1週間の範囲:
$118.78
$123.74
52週間の値動き範囲:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
123.36 | 150.54B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,008.00 | 889.33B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
209.98 | 497.62B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.21 | 397.98B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.27 | 251.73B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
98.78 | 242.30B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
The Manufacturers Life Insurance Company Sells 95,568 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
CIBC Asset Management Inc Sells 28,874 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News - GuruFocus
Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD) - Insider Monkey
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 at HSBC - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Why You Might Be Interested In Gilead Sciences, Inc. (NASDAQ:GILD) For Its Upcoming Dividend - simplywall.st
HSBC Adjusts Price Target on Gilead Sciences to $133 From $110, Maintains Hold Rating - marketscreener.com
30,000 Shares in Gilead Sciences, Inc. $GILD Bought by Diadema Partners LP - MarketBeat
Lombard Odier Asset Management Switzerland SA Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer - Yahoo Finance
Ossiam Sells 15,066 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Jump Financial LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Three Catalysts Driving Investor Attention Toward Gilead Sciences - AD HOC NEWS
Gilead Sciences, Inc. $GILD Shares Sold by Bank of Nova Scotia - MarketBeat
ASH25: CAR-T Leaders Gilead, J&J Show in Multiple Myeloma; Fulcrum Rises on Sickle Cell Data - BioSpace
WINTON GROUP Ltd Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
ASH: Gilead preps filing for anito-cel on iMMagine-1 data - Pharmaphorum
What Does the Market Think About Gilead Sciences Inc? - Benzinga
Gilead Sciences, Inc. $GILD Shares Bought by Natixis - MarketBeat
35,296 Shares in Gilead Sciences, Inc. $GILD Bought by SVB Wealth LLC - MarketBeat
Gilead moves ahead on Chess Hatch project - San Mateo Daily Journal
L2 Asset Management LLC Buys 28,592 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GILD's Yescarta Shows Promising Results for Lymphoma Patients - GuruFocus
GILD's Kite Unveils Promising CAR T-Cell Therapy Results at ASH Meeting - GuruFocus
ASH: Gilead’s Kite Plots 2026 Launch For Anito-Cel For Multiple Myeloma - Citeline News & Insights
ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch - Fierce Biotech
New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment - statnews.com
Federated Hermes Inc. Sells 1,885,664 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Position Decreased by Brown Advisory Inc. - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Baird Financial Group Inc. - MarketBeat
Why The Narrative Around Gilead Sciences Is Shifting After HIV And Oncology Updates - Yahoo Finance
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition - GlobeNewswire Inc.
First Trust Advisors LP Sells 1,512,069 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Arrowstreet Capital Limited Partnership Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
1832 Asset Management L.P. Makes New $4.69 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Marshall Wace LLP Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Dodge & Cox Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Epoch Investment Partners Inc. Has $95.16 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by CW Advisors LLC - MarketBeat
Amundi Purchases 1,614,355 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - marketscreener.com
Redeye: Sprint Bioscience (Q3 review)Gilead deal a strong confirmation - TradingView
Is Gilead Sciences Inc. (GIS) stock good for long term investingJuly 2025 Rallies & Stock Timing and Entry Methods - Newser
Gilead's Seat at the Table of Conversations Centered Around HIV - Gilead Sciences
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
VestGen Advisors LLC Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Channing Capital Management LLC Purchases 43,875 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Guggenheim Capital LLC - MarketBeat
Groupe la Francaise Has $3.92 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline - MSN
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bluestone Jeffrey | Director |
Nov 28 '25 |
Sale |
125.08 |
5,000 |
625,400 |
8,920 |
| Kramer Kelly A. | Director |
Nov 26 '25 |
Option Exercise |
81.00 |
2,806 |
227,286 |
4,145 |
| Kramer Kelly A. | Director |
Nov 28 '25 |
Option Exercise |
81.00 |
2,805 |
227,205 |
4,144 |
| Kramer Kelly A. | Director |
Nov 26 '25 |
Sale |
127.11 |
2,806 |
356,671 |
1,339 |
| Kramer Kelly A. | Director |
Nov 28 '25 |
Sale |
127.10 |
2,805 |
356,516 |
1,339 |
| O'Day Daniel Patrick | Chairman & CEO |
Nov 28 '25 |
Sale |
126.54 |
10,000 |
1,265,444 |
571,203 |
0.15%
0.21%
大文字化:
|
ボリューム (24 時間):